Assenagon Asset Management S.A. Makes New $709,000 Investment in Qiagen N.V. $QGEN

Assenagon Asset Management S.A. acquired a new stake in shares of Qiagen N.V. (NYSE:QGEN) in the first quarter, Holdings Channel.com reports. The firm acquired 17,698 shares of the company’s stock, valued at approximately $709,000.

Other institutional investors and hedge funds have also modified their holdings of the company. Danske Bank A S purchased a new position in shares of Qiagen during the 3rd quarter valued at approximately $36,000. Manchester Capital Management LLC acquired a new stake in Qiagen during the fourth quarter valued at $42,000. Global Retirement Partners LLC grew its position in Qiagen by 279.9% during the fourth quarter. Global Retirement Partners LLC now owns 1,155 shares of the company’s stock valued at $52,000 after buying an additional 851 shares during the period. Allworth Financial LP grew its position in Qiagen by 23.2% during the third quarter. Allworth Financial LP now owns 1,358 shares of the company’s stock valued at $61,000 after buying an additional 256 shares during the period. Finally, Advisory Services Network LLC purchased a new position in Qiagen in the third quarter valued at $64,000. Institutional investors and hedge funds own 70.00% of the company’s stock.

Analyst Upgrades and Downgrades

QGEN has been the subject of a number of analyst reports. JPMorgan Chase & Co. decreased their price objective on shares of Qiagen from $60.00 to $45.00 and set an “overweight” rating for the company in a research report on Wednesday, April 29th. Kepler Capital Markets set a $38.60 target price on Qiagen and gave the company a “hold” rating in a research report on Thursday, June 25th. Barclays set a $38.00 price target on Qiagen and gave the stock an “equal weight” rating in a report on Wednesday, April 29th. Stifel Nicolaus set a $36.00 price target on Qiagen and gave the stock a “hold” rating in a research report on Monday, May 18th. Finally, Robert W. Baird set a $43.00 price objective on Qiagen and gave the company an “outperform” rating in a report on Wednesday, April 29th. One analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating, seven have given a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, Qiagen currently has an average rating of “Hold” and a consensus price target of $43.15.

Qiagen Stock Up 2.4%

QGEN stock opened at $40.08 on Friday. Qiagen N.V. has a 52 week low of $32.53 and a 52 week high of $57.81. The company has a quick ratio of 2.57, a current ratio of 3.21 and a debt-to-equity ratio of 0.49. The firm has a 50-day simple moving average of $36.24 and a 200-day simple moving average of $42.89. The stock has a market capitalization of $8.26 billion, a P/E ratio of 20.93, a P/E/G ratio of 3.91 and a beta of 0.64.

Qiagen (NYSE:QGEN) last posted its quarterly earnings data on Thursday, May 7th. The company reported $0.54 EPS for the quarter, hitting the consensus estimate of $0.54. Qiagen had a return on equity of 14.40% and a net margin of 19.16%.The company had revenue of $492.32 million during the quarter, compared to analyst estimates of $496.15 million. During the same period in the previous year, the business earned $0.56 EPS. Equities analysts forecast that Qiagen N.V. will post 2.43 earnings per share for the current fiscal year.

Qiagen Increases Dividend

The firm also recently announced an annual dividend, which will be paid on Tuesday, July 14th. Shareholders of record on Tuesday, July 7th will be paid a dividend of $0.35 per share. This is a boost from Qiagen’s previous annual dividend of $0.26. The ex-dividend date of this dividend is Tuesday, July 7th. This represents a yield of 104.0%. Qiagen’s dividend payout ratio is presently 13.61%.

About Qiagen

Qiagen NV (NYSE: QGEN) is a global provider of sample and assay technologies designed to enable molecular testing in the fields of molecular diagnostics, applied testing, academic research and pharmaceutical development. The company’s solutions span the full workflow of nucleic acid and protein analysis, offering customers standardized kits, instruments and software tools that streamline the preparation, detection and quantification of DNA, RNA and proteins.

The company’s product portfolio includes nucleic acid extraction and purification systems, polymerase chain reaction (PCR) reagents and instrumentation, digital PCR platforms, next-generation sequencing (NGS) library?preparation kits and proteomics solutions.